From Evidence to Exam Room: GLP-1 RA Therapy in Primary Care

Pre-registration for:
From Evidence to Exam Room: GLP-1 RA Therapy in Primary Care

Friday, October 23, 2026

Registration & Breakfast: 6 am to 6:30 am CT
Symposium: 6:30 am to 8 am CT

Omni Nashville Hotel
Broadway Ballroom A-D
250 Rep. John Lewis Way S.
Nashville, TN

Register using the form provided below. Click HERE for additional meeting details.
 
This event is not a part of the official AAFP FMX.

TERMS:This is a complimentary event. Registration does not guarantee seating. This event is designed for the education of healthcare professionals and improvement in the care of patients according to guidelines for care. We are unable to accommodate guests.
Register using the form provided below. Click HERE for additional meeting details.
+ Add a Registration
Security Check *
* Required fields.
Symposium Poster

Program Overview:

Every day, a family physician in a busy primary care practice sees patients with type 2 diabetes (T2D). The evidence base for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with T2D and at high cardiovascular risk is now vast and compelling. Numerous cardiovascular outcomes trials (CVOTs) have demonstrated reduction in major adverse cardiovascular events (MACE). Critically, the SOUL trial established for the first time that an oral GLP-1 RA demonstrates the same cardiovascular protection as injectable agents. This is a practice-changing development for primary care, where injection aversion has long been one of the most commonly cited barriers to initiating this class of therapy.
This educational activity is designed as a practical clinical decision-making workshop anchored in the realities of primary care practice. Three experts in the management of T2D and cardiovascular risk will guide attendees through the evidence, guidelines, and exam room conversations and prescribing decisions that will improve the outcomes for their patients.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Apply the 2026 ADA Standards of Care guideline recommendations to identify primary care patients with T2D who are candidates for GLP1 RA therapy, including those with ASCVD, CKD, or multiple cardiovascular risk factors.
  • Interpret cardiovascular outcomes trial evidence with GLP1 RA therapy and translate key findings into clinical decisions for primary care patients.
  • Initiate oral or injectable GLP1 RA therapy in appropriate primary care patients, including those who are injection averse, using correct dosing, titration, and administration guidance.
  • Counsel primary care patients on benefits, tolerability, administration requirements, and safety profile to support shared decision making.

Target Audience:

This program is intended for primary care clinicians and other healthcare professionals who manage patients with T2D and ASCVD risk

Accreditation and Credit Designation Statements

This live activity, From Evidence to Exam Room: GLP-1 RA Therapy in Primary Care, with a beginning date of 10/23/26, has been reviewed and is acceptable for up to 1.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits*™. Physicians should claim only credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Educational Grant:

This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure Information

Voxmedia strives to ensure fair-balance, independence, objectivity, and scientific rigor in all directly or jointly sponsored educational activities. All prospective faculty are required to disclose to Voxmedia all financial relationships for the preceding 24 months (1) with any commercial interest producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients AND (2) with any commercial supporters prior to participating in the planning of an activity or developing content. Only after Voxmedia mitigates all financial relationships may faculty receive approval to participate and are expected to contribute evidence-based material. Faculty are required to indicate areas of their presentation that are based on professional opinion vs. guidelines, meta-analysis. All information submitted will be peer-reviewed. The intent of this disclosure is not to prevent faculty from participating, but rather to provide learners with information on which they can make their own judgment of commercial bias. Voxmedia will disclose to learners that all relevant financial relationships have been mitigated in either written materials, visually and/or verbally. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation. Speakers must make a meaningful disclosure to the audience of their discussions of any unlabeled or investigational use(s) of drugs or devices.

Americans with Disabilities Act:

Voxmedia fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant of this activity is in need of accommodation, please call and/or submit in writing to: Voxmedia, 454 Morris Avenue, Springfield, New Jersey 07081 USA; Phone: 973-467-0500